Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by D.A. Davidson & CO.

D.A. Davidson & CO. raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 34.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,250 shares of the company’s stock after purchasing an additional 4,150 shares during the quarter. D.A. Davidson & CO.’s holdings in Intellia Therapeutics were worth $334,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after purchasing an additional 659,651 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Intellia Therapeutics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after purchasing an additional 98,865 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Intellia Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock valued at $17,006,000 after purchasing an additional 37,714 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Intellia Therapeutics by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 364,306 shares of the company’s stock valued at $8,153,000 after purchasing an additional 2,301 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Down 1.1 %

NTLA stock opened at $14.49 on Thursday. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -2.66 and a beta of 1.76. Intellia Therapeutics, Inc. has a 12 month low of $12.82 and a 12 month high of $34.87. The firm has a 50-day moving average of $16.88 and a two-hundred day moving average of $21.14.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The firm’s revenue was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.38) EPS. As a group, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This trade represents a 4.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NTLA. Barclays lowered their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Robert W. Baird lowered their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lowered their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Citigroup lowered their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Stifel Nicolaus lowered their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.94.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.